



Pfizer Limited

Pfizer Centre, Patel Estate,
Off S. V. Road, Jogeshwari (W), Mumbai 400 102
Tel 91 22 6693 2000 Fax 91 22 6693 2444

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2011

Particulars	(Rs In Lakhs)		
	Quarter ended 30th June 2011 Unaudited	Quarter ended 31st May 2010 Unaudited	Sixteen Months period ended 31st March 2011 Audited
1. (a) Net Sales/Income from Operations	24,187	21,233	116,956
(b) Other Operating Income	1,934	1,245	7,508
2. Expenditure			
a. (Increase)/decrease in stock in trade and work in process	(435)	(1,234)	(3,215)
b. Consumption of raw materials (Refer note 4)	5,356	5,720	27,265
c. Purchase of traded goods	3,590	2,932	14,999
d. Employees cost	5,827	5,106	22,699
e. Depreciation	235	222	1,200
f. Other expenditure	7,592	6,333	36,824
g. Total	22,165	19,079	99,772
3. Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	3,956	3,399	24,692
4. Other Income	2,203	2,148	10,072
5. Profit before Interest and Exceptional Items (3+4)	6,159	5,547	34,764
6. Interest	-	-	-
7. Profit after Interest but before Exceptional Items (5-6)	6,159	5,547	34,764
8. Exceptional items (Refer note 5)	-	(124)	(303)
9. Profit from Ordinary Activities before tax (7+8)	6,159	5,423	34,461
10. Tax expense	2,035	1,954	11,827
11. Net Profit from Ordinary Activities after tax (9-10)	4,124	3,469	22,634
12. Extraordinary Item (net of tax expense)	-	-	-
13. Net Profit for the period (11-12)	4,124	3,469	22,634
14. Paid-up equity share capital (Face Value per share Rs 10)	2,984	2,984	2,984
15. Reserves (excluding revaluation reserves which are NIL)			113,360
16. Earnings Per Share (EPS)			
(a) Basic and diluted EPS before exceptional items for the period and for the previous year (not annualized) Rs	13.82	11.89	76.52
(b) Basic and diluted EPS before extraordinary items for the period for the previous year (not annualized) Rs	13.82	11.63	75.85
(c) Basic and diluted EPS after extraordinary items for the period and for the previous year (not annualized) Rs	13.82	11.63	75.85
17. Public Shareholding			
- No. of shares	8,728,269	8,728,269	8,728,269
- Percentage of shareholding	29.25%	29.25%	29.25%
18. Promoters and promoter group Shareholding			
a) Pledged/Encumbered			
- Number of shares	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil
b) Non-encumbered			
- Number of Shares	21,113,171	21,113,171	21,113,171
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%
- Percentage of shares (as a % of the total shareholding of promoter and promoter group company)	70.75%	70.75%	70.75%

h



**UNAUDITED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED
FOR THE QUARTER ENDED 30TH JUNE, 2011**

Particulars	(Rs In Lakhs)		
	Quarter ended 30th June 2011 Unaudited	Quarter ended 31st May 2010 Unaudited	Sixteen Months period ended 31st March 2011 Audited
1. Segment Revenue			
(a) Pharmaceuticals	21,041	19,135	101,791
(b) Animal Health	3,146	2,763	15,920
(c) Services -	1,903	1,199	7,392
Total	26,090	23,097	125,103
Less: Inter Segment Revenue	-	-	-
Net sales/Income From Operations	26,090	23,097	125,103
2. Segment Results (Profit before tax and interest from each segment)			
(a) Pharmaceuticals	4,394	4,793	28,403
(b) Animal Health	868	636	3,119
(c) Services	184	142	791
Total	5,446	5,571	32,313
Less: (i) Interest	(1,821)	(1,200)	(7,428)
(ii) Other un-allocable expenditure net off un-allocable income	1,108	1,348	5,280
Total Profit Before Tax	6,159	5,423	34,461
3. Capital Employed			
(a) Pharmaceuticals	10,616	15,423	10,989
(b) Animal Health	4,495	4,171	4,585
(c) Services	3,984	929	3,874
(d) Unallocated	101,373	86,624	96,896
Total	120,468	107,147	116,344

**NOTES:**

1. The above results were reviewed and recommended by Audit Committee for approval by the Board at its meeting held on 1st August, 2011 and were approved and taken on record at the meeting of the Board of Directors of the Company held on that date.
2. The results for the quarter ended 30th June, 2011 have been subjected to a limited review by the statutory auditors of the Company.
3. The company has changed its accounting year from 1st December -30th November to 1st April-31st March with effect from 1st December, 2009. The current quarter is from 1st April, 2011 to 30th June, 2011 while the previous quarter was from 1st March, 2010 to 31st May, 2010. Hence the figures are strictly not comparable. The previous period was for 16 months from 1st December, 2009 – 31st March, 2011.
4. "Consumption of raw materials" includes consumption of raw materials and packing materials.
5. "Exceptional items" include compensation paid to employees under VRS. The expense for the quarter ended 30th June, 2011 is Nil (previous year corresponding quarter ended 31st May, 2010 Rs 124 lakhs).
6. At the beginning of the current period, there were no shareholder complaints pending. During the current period 20 complaints were received and 20 complaints were disposed off. Hence, there is no complaint pending as at the end of the current period.
7. (a) Charges towards provision of back office support to fellow subsidiaries, which were netted off against expenses amounting to Rs133 Lakhs for the quarter ended 31st May, 2010 have now been regrouped to Other Operating Income. Consequential adjustments have been made to the segment disclosures.

(b) The excess provision written back of Rs. 665 lakhs for the quarter ended 31st May 2010 has been reclassified from unallocated income to Pharmaceutical's segment revenue & results.

For Pfizer Limited

A handwritten signature in black ink, appearing to read "Kewal Handa".

Kewal Handa
Managing Director

Mumbai, 1st August, 2011